Gjefsen, Elisabeth http://orcid.org/0000-0003-0470-7225
Bråten, Lars Christian Haugli
Goll, Guro Løvik
Wigemyr, Monica
Bolstad, Nils
Valberg, Morten
Schistad, Elina Iordanova
Marchand, Gunn Hege
Granviken, Fredrik
Selmer, Kaja Kristine
Froholdt, Anne
Haugen, Anne Julsrud
Dagestad, Magnhild Hammersland
Vetti, Nils
Bakland, Gunnstein
Lie, Benedicte Alexandra
Haavardsholm, Espen A.
Nilsen, Aksel Thuv
Holmgard, Thor Einar
Kadar, Thomas Istvan
Kvien, Tore
Skouen, Jan Sture
Grøvle, Lars
Brox, Jens Ivar
Espeland, Ansgar
Storheim, Kjersti
Zwart, John Anker
Funding for this research was provided by:
Klinbeforsk (18/00015-2)
Article History
Received: 30 June 2020
Accepted: 14 October 2020
First Online: 21 October 2020
Ethics approval and consent to participate
: The BackToBasic study protocol has been approved for all study sites by the Regional Committee for Medical Research Ethics in Norway (REC South East, reference number 2017/2450) and the Norwegian Medicines Agency (SLV).Participation in the study is voluntary. All patients receive oral and written information about the risks and possible benefits of the study and give their written informed consent before screening. Patients can withdraw their consent at any time and without stating any particular reason. The patient information and informed consent form is also approved by the Regional Committee for Medical research Ethics in Norway.
: Not applicable.
: Guro L Goll has received honoraria as a speaker for Abbvie, Biogen, Boehringer Ingelheim, Orion Pharma, Pfizer, Roche. Nils Bolstad reports personal fees from Orion Pharma, Roche, Napp Pharmaceuticals, Pfizer and Takeda.The other authors declare that they have no competing interests.